HEAL

Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency   This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days to 150 days Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has […]